Incyte (INCY) Cash from Restructuring (2010 - 2011)
Incyte's (INCY) quarterly Cash from Restructuring came in at -$108000.0 in Q4 2011, down 640.0% YoY from $20000.0 in Q4 2010, and down 183.72% on a QoQ basis from $129000.0 in Q2 2011.
Incyte (INCY) Cash from Restructuring (2010 - 2011) Analysis & Trends
Incyte (INCY) has 2 years of Cash from Restructuring data on file, last reported at -$108000.0 in Q4 2011.
- Quarterly Cash from Restructuring fell 640.0% year-over-year to -$108000.0 in Q4 2011, while the trailing twelve-month figure through Dec 2011 was -$88000.0 (up 76.78% YoY) and the FY2011 annual result came in at -$88000.0, up 76.78% from the prior year.
- Cash from Restructuring eased to -$108000.0 in Q4 2011, from $129000.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $129000.0 in Q2 2011 to a low of -$145000.0 in Q2 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -108,000.00 |
| Jun 30, 2011 | 129,000.00 |
| Mar 31, 2011 | -109,000.00 |
| Dec 31, 2010 | 20,000.00 |
| Sep 30, 2010 | -139,000.00 |
| Jun 30, 2010 | -145,000.00 |
| Mar 31, 2010 | -115,000.00 |